Evidence map›Paper›PMID 26132557›Full record

ArticlePloS one2015

An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies.

Virginie Dutoit-Lefèvre, Sylvain Dubucquoi, David Launay, Vincent Sobanski, Patricia Dussart, Philippe Chafey, Cédric Broussard, Sophie Duban-Deweer, Patrick Vermersch, Lionel Prin and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Virginie Dutoit-LefèvreInstitut d'Immunologie, Centre de Biologie Pathologie et Génétique, Centre Hospitalier Régional Universitaire, Lille, France; UMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France.
Sylvain DubucquoiInstitut d'Immunologie, Centre de Biologie Pathologie et Génétique, Centre Hospitalier Régional Universitaire, Lille, France; UMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France.
David LaunayUMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France; Service de Médecine Interne et d'Immunologie clinique, Centre National de Référence Maladies rares, Centre Hospitalier Régional Universitaire, Lille, France.
Vincent SobanskiUMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France; Service de Médecine Interne et d'Immunologie clinique, Centre National de Référence Maladies rares, Centre Hospitalier Régional Universitaire, Lille, France.
Patricia DussartInstitut d'Immunologie, Centre de Biologie Pathologie et Génétique, Centre Hospitalier Régional Universitaire, Lille, France; UMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France.
Philippe ChafeyINSERM U1016, Institut Cochin, Paris, France; UMR 8104, CNRS Paris, France; Plate-forme Protéomique 3P5, Univ Paris Descartes, Sorbonne Paris Cité, Paris, France.
Cédric BroussardINSERM U1016, Institut Cochin, Paris, France; UMR 8104, CNRS Paris, France; Plate-forme Protéomique 3P5, Univ Paris Descartes, Sorbonne Paris Cité, Paris, France.
Sophie Duban-DeweerEA 2686, Univ Lille Nord de France, Lille, France; LBHE, EA 2465, UArtois, Lens, France.
Patrick VermerschUMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France; Service de Neurologie D, Centre Hospitalier Régional Universitaire, Lille, France.
Lionel PrinInstitut d'Immunologie, Centre de Biologie Pathologie et Génétique, Centre Hospitalier Régional Universitaire, Lille, France; UMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France.
Didier LefrancUMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France.
Centre Hospitalier Universitaire de Lille · FRLille Inflammation Research International Center · FRUniversité de Lille · FRDélégation Paris 5 · FRInserm · FRSorbonne Paris Cité · FRUniversité d'Artois · FRUniversité Lille Nord de France · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serological proteome analysis (SERPA) combines classical proteomic technology with effective separation of cellular protein extracts on two-dimensional gel electrophoresis, western blotting, and identification of the antigenic spot of interest by mass spectrometry. A critical point is related to the antigenic target characterization by mass spectrometry, which depends on the accuracy of the matching of antigenic reactivities on the protein spots during the 2D immunoproteomic procedures. The superimposition, based essentially on visual criteria of antigenic and protein spots, remains the major limitation of SERPA. The introduction of fluorescent dyes in proteomic strategies, commonly known as 2D-DIGE (differential in-gel electrophoresis), has boosted the qualitative capabilities of 2D electrophoresis. Based on this 2D-DIGE strategy, we have improved the conventional SERPA by developing a new and entirely fluorescence-based bi-dimensional immunoproteomic (FBIP) analysis, performed with three fluorescent dyes. To optimize the alignment of the different antigenic maps, we introduced a landmark map composed of a combination of specific antibodies. This methodological development allows simultaneous revelation of the antigenic, landmark and proteomic maps on each immunoblot. A computer-assisted process using commercially available software automatically leads to the superimposition of the different maps, ensuring accurate localization of antigenic spots of interest.

Indexed as

AnimalsAntibodies, MonoclonalAutoantibodiesAutoantigensBlotting, WesternCarbocyaninesFluorescent DyesHep G2 CellsHumansImage Processing, Computer-AssistedImmunoglobulin GIsoelectric FocusingLuminescent MeasurementsLupus Erythematosus, SystemicMiceMolecular WeightAntibodies, MonoclonalAutoantibodiesAutoantigensCarbocyaninescyanine dye 3cyanine dye 5Fluorescent DyesImmunoglobulin G

Identifiers

PMID26132557
PMCPMC4489013
OpenAlexW2258096148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.